Table 1B. Description of studies comparing hyaluronic acid with steroids (n=10).
| Author/year | Patients number | Outcomes measured - Instrument | Adverse effects reported | Molecular weight | Injection number | Follow-up weeks | ||
|---|---|---|---|---|---|---|---|---|
| Hyaluronic acid | Saline solution | Pain | Function | |||||
| Askari A 2016 | 71 | 69 | WOMAC | VAS | No | High | 1 | 12 |
| Bisicchia S 2016 | 75 | 75 | WOMAC | No | High | 2 | 26 and 52 | |
| Caborn D 2004 | 113 | 102 | WOMAC / VAS | WOMAC | No | High | 3 | 26 |
| Maia PAV 2019 | 16 | 12 | WOMAC | WOMAC | No | High | 1 | 24 |
| Shimizu M 2010 | 32 | 29 | VAS | No | High | 5 | 24 | |
| Skwara A 2009 | 30 | 30 | VAS | Lequesne index | No | Intermediate | 1 | 12 |
| Tammachote N 2016 | 50 | 49 | VAS | WOMAC | Yes | High | 1 | 24 |
| Tasciotaoglu F 2003 | 28 | 27 | VAS | Lequesne index | Yes | High | 3 | 26 |
| Housman L 2014 | 129 | 132 | WOMAC | Yes | High | 1 | 26 | |
| Leighton R 2014 | 221 | 221 | WOMAC | Yes | Intermediate | 1 | 26 | |